CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer

Despite widespread deregulation of CDK4/6 activity in non-small cell lung cancer (NSCLC), clinical trials with CDK4/6 inhibitor (CDK4/6i) as a monotherapy have shown poor antitumor activity. Preclinical studies indicate that CDK4/6i may collaborate by influencing DNA damage repair pathways during ra...

Full description

Saved in:
Bibliographic Details
Main Authors: Carlos M Roggero, Anwesha B Ghosh, Anvita Devineni, Shihong Ma, Eliot Blatt, Ganesh V. Raj, Yi Yin
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Translational Oncology
Subjects:
DNA damage repair
CDK4/6 inhibition
PARP inhibition
Patient-derived explant
Non-small cell lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523324003577
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items